Insider · CIK 0001573163

Ashe Andrew D.

Reports to the SEC for 3 companies · BURLINGTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001573163

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−27K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−150K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.U Disposition from Tender	See Remarks	UDisposition from Tender	−349K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−225K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	See Remarks	DDisposition to Issuer	−40K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	See Remarks	DDisposition to Issuer	−27K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−108K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	See Remarks	DDisposition to Issuer	−153K sh	—	—	0
2025-04-02	Verve Therapeutics, Inc.S Sale	See Remarks	SSale	−2,681 sh	$4.15	−$11.1K	348,828
2025-04-01	Verve Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	See Remarks	MExercise/Conversion	−9,000 sh	—	—	27,000
2025-04-01	Verve Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+9,000 sh	—	—	351,509
2025-01-08	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	See Remarks	AAward	+225K sh	—	—	225,000
2025-01-08	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	See Remarks	AAward	+40K sh	—	—	40,000
2024-05-14	Verve Therapeutics, Inc.P Purchase	See Remarks	PPurchase	+76K sh	$6.26	+$476K	342,509
2024-02-14	Verve Therapeutics, Inc.Restricted Stock UnitsA Award	See Remarks	AAward	+36K sh	—	—	36,000
2024-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	See Remarks	AAward	+150K sh	—	—	150,000
2023-02-14	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	See Remarks	AAward	+183K sh	—	—	182,800
2022-08-25	Verve Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+10.8K sh	$2.87	+$31.1K	266,509
2022-08-25	Verve Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+33.7K sh	$1.48	+$49.9K	255,674
2022-08-25	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−33.7K sh	—	—	26,999
2022-08-25	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−10.8K sh	—	—	153,278
2022-08-25	Verve Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	See Remarks	MExercise/Conversion	−51.2K sh	—	—	0
2022-08-25	Verve Therapeutics, Inc.M Exercise/Conversion	See Remarks	MExercise/Conversion	+51.2K sh	$1.39	+$71.2K	221,925
2022-02-11	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	See Remarks	AAward	+125K sh	—	—	125,000
2021-12-02	Verve Therapeutics, Inc.P Purchase	See Remarks	PPurchase	+4,000 sh	$32.10	+$128K	170,722
2021-06-17	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	See Remarks	AAward	+21.6K sh	—	—	21,599
2017-08-01	APPLIED GENETIC TECHNOLOGIES CORPStock Option (right to buy)A Award	General Counsel	AAward	+100K sh	—	—	100,000
2016-01-22	DYAX CORPStock Option (right to buy)D Disposition to Issuer	General Counsel & EVP	DDisposition to Issuer	−18.1K sh	—	—	0
2016-01-22	DYAX CORPStock Option (right to buy)D Disposition to Issuer	General Counsel & EVP	DDisposition to Issuer	−20.3K sh	—	—	0
2016-01-22	DYAX CORPD Disposition to Issuer	General Counsel & EVP	DDisposition to Issuer	−332K sh	—	—	0
2016-01-22	DYAX CORPStock Option (right to buy)D Disposition to Issuer	General Counsel & EVP	DDisposition to Issuer	−78K sh	—	—	0
2016-01-22	DYAX CORPStock Option (right to buy)D Disposition to Issuer	General Counsel & EVP	DDisposition to Issuer	−238K sh	—	—	0
2016-01-22	DYAX CORPStock Option (right to buy)D Disposition to Issuer	General Counsel & EVP	DDisposition to Issuer	−23.4K sh	—	—	0
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+54.7K sh	$3.00	+$164K	151,465
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+51.6K sh	$4.33	+$223K	203,028
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+66K sh	$10.20	+$673K	269,028
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+62.5K sh	$15.23	+$952K	331,528
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−38.8K sh	—	—	18,125
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−51.6K sh	—	—	23,437
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+625 sh	$2.39	+$1,493.75	34,752
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+5,150 sh	$1.87	+$9,630.5	39,902
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+18.1K sh	$1.41	+$25.6K	58,027
2016-01-14	DYAX CORPM Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	+38.8K sh	$1.48	+$57.4K	96,777
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−625 sh	—	—	0
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−5,150 sh	—	—	0
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−18.1K sh	—	—	0
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−38.8K sh	—	—	17,565
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−54.7K sh	—	—	20,312
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−51.6K sh	—	—	23,437
2016-01-14	DYAX CORPStock Option (right to buy)M Exercise/Conversion	General Counsel & EVP	MExercise/Conversion	−66K sh	—	—	78,000

Recent filings

Accepted (ET)
Jul 284
Ashe Andrew D.0000950170-25-099254
SEC(opens sec.gov)
Apr 34
Ashe Andrew D.0000950170-25-050561
SEC(opens sec.gov)
Jan 104
Ashe Andrew D.0000950170-25-003849
SEC(opens sec.gov)
May 154
Ashe Andrew D.0000950170-24-060613
SEC(opens sec.gov)
Feb 164
Ashe Andrew D.0000950170-24-016426
SEC(opens sec.gov)
Feb 164
Ashe Andrew D.0001209191-23-010120
SEC(opens sec.gov)
Aug 294
Ashe Andrew D.0001209191-22-047882
SEC(opens sec.gov)

Companies

Address

C/O DYAX CORP. 55 NETWORK DRIVE

BURLINGTON, MA, 01803-2756